A multi-case study of five major cannabis companies found significant investment and employee flows from alcohol, tobacco, and pharmaceutical companies, raising concerns about profit-driven practices undermining public health protections.
Cannabis regulators, public health advocates, corporate governance researchers.
All five major cannabis companies had investment ties to alcohol, tobacco, or pharmaceutical industries
What the researchers found
All five cannabis companies (Canopy Growth, Aurora, Tilray, Cronos Group, Organigram) had investment relationships with alcohol, tobacco, or pharmaceutical companies. Some received substantial investments that came with industry influence. Employee flows showed cross-industry expertise transfer, particularly in management, finance, and strategy, suggesting established industries are strategically positioning themselves in the cannabis sector.
Why it matters
The alcohol and tobacco industries have well-documented histories of marketing to vulnerable populations, lobbying against regulations, and prioritizing profits over public health. Their entry into cannabis markets raises concerns about importing these practices.
The numbers in context
Five cannabis companies analyzed; data from corporate reports, press releases, and LinkedIn; investment relationships documented with alcohol, tobacco, and pharmaceutical sectors; employee flow patterns identified in management, finance, and strategy.
How the study worked
Exploratory multi-case study analyzing business investments and employee movement between five cannabis companies and alcohol, tobacco, and pharmaceutical companies. Data from Nexis Uni, corporate reports, press releases, and LinkedIn.
What this study cannot tell us
Exploratory study focused on only five companies. Publicly available data may not capture all relationships. Cannot prove that cross-industry connections have actually harmed public health. Canadian/North American focus may not apply to other markets.
How to read the evidence
Moderate: Systematic multi-case study with multiple data sources, though limited to five companies and publicly available information.
When this study was published
Published in 2025 with data through 2024.
The bigger picture
Cannabis commercialization is at a critical juncture. The industry connections documented here mirror historical patterns where established consumer product companies have entered new markets and shaped regulation in their favor, often at the expense of public health.
Questions still open
- Are cannabis marketing practices already showing influence from alcohol/tobacco approaches? How should regulators address cross-industry investment in cannabis? Would structural separation between cannabis and other substance industries protect public health?
Common questions
Why does it matter that tobacco companies invest in cannabis?
Which companies are involved?
Read the original research
Like birds of a feather? A multi-case study on the connections between cannabis, tobacco, alcohol and pharmaceutical companies in legalized cannabis markets.
The International journal on drug policy, 143, 104863
Citation
Ongenaert, Marthe; Decorte, Tom. (2025). Like birds of a feather? A multi-case study on the connections between cannabis, tobacco, alcohol and pharmaceutical companies in legalized cannabis markets.. The International journal on drug policy, 143, 104863. https://doi.org/10.1016/j.drugpo.2025.104863